Transcode Therapeutics Stock Net Income
| RNAZ Stock | USD 8.94 0.11 1.25% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Transcode Therapeutics' long-term financial health and intrinsic value.
| Last Reported | Projected for Next Year | ||
| Net Loss | -15.8 M | -15 M | |
| Net Loss | -15.1 M | -14.3 M | |
| Net Loss | -15.1 M | -15.8 M | |
| Net Loss | (54.11) | (56.81) |
Transcode | Net Income | Build AI portfolio with Transcode Stock |
Transcode Therapeutics Company Net Income Analysis
Transcode Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Transcode Therapeutics Net Income | (16.75 M) |
Most of Transcode Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Transcode Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Transcode Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Transcode Therapeutics is extremely important. It helps to project a fair market value of Transcode Stock properly, considering its historical fundamentals such as Net Income. Since Transcode Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Transcode Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Transcode Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Transcode Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Transcode Therapeutics reported net income of (16.75 Million). This is 104.91% lower than that of the Biotechnology sector and 123.92% lower than that of the Health Care industry. The net income for all United States stocks is 102.93% higher than that of the company.
Transcode Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Transcode Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Transcode Therapeutics could also be used in its relative valuation, which is a method of valuing Transcode Therapeutics by comparing valuation metrics of similar companies.Transcode Therapeutics is currently under evaluation in net income category among its peers.
Transcode Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Transcode Therapeutics from analyzing Transcode Therapeutics' financial statements. These drivers represent accounts that assess Transcode Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Transcode Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 13.8B | 5.6B | 23.1M | 23.5M | 27.1M | 25.7M | |
| Enterprise Value | 13.8B | 5.6B | 20.8M | 17.8M | 20.4M | 19.4M |
Transcode Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Transcode Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Transcode Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Transcode Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Transcode Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Transcode Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Transcode Therapeutics' value.| Shares | Sabby Management Llc | 2025-06-30 | 0.0 | Warberg Asset Management Llc | 2025-06-30 | 0.0 | Corsair Capital Management Llc | 2025-06-30 | 0.0 | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 0.0 | Anson Funds Management Lp | 2025-03-31 | 1.5 M | Goldman Sachs Group Inc | 2025-06-30 | 28 K | Ubs Group Ag | 2025-06-30 | 1.4 K | Southstate Bank Corp | 2025-06-30 | 482 | Tower Research Capital Llc | 2025-06-30 | 402 | Sbi Securities Co Ltd | 2025-06-30 | 10.0 | Royal Bank Of Canada | 2025-06-30 | 8.0 |
Transcode Fundamentals
| Return On Equity | -17.63 | ||||
| Return On Asset | -2.33 | ||||
| Current Valuation | 2.42 M | ||||
| Shares Outstanding | 916.97 K | ||||
| Shares Owned By Insiders | 9.20 % | ||||
| Shares Owned By Institutions | 6.82 % | ||||
| Number Of Shares Shorted | 59.48 K | ||||
| Price To Book | 5.75 X | ||||
| EBITDA | (16.19 M) | ||||
| Net Income | (16.75 M) | ||||
| Cash And Equivalents | 13.45 M | ||||
| Cash Per Share | 1.04 X | ||||
| Total Debt | 38.29 K | ||||
| Current Ratio | 8.06 X | ||||
| Book Value Per Share | 1.71 X | ||||
| Cash Flow From Operations | (13.34 M) | ||||
| Short Ratio | 2.29 X | ||||
| Earnings Per Share | (236.52) X | ||||
| Target Price | 10.0 | ||||
| Beta | 1.55 | ||||
| Market Capitalization | 8.2 M | ||||
| Total Asset | 7.29 M | ||||
| Retained Earnings | (63.2 M) | ||||
| Working Capital | 4.32 M | ||||
| Net Asset | 7.29 M |
About Transcode Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Transcode Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Transcode Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Transcode Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Transcode Stock Analysis
When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.